Folgende Parameter werden von unserem Labor derzeit angeboten:
| Parameter |
Quant. |
AML |
CML |
PV |
ET |
PMF |
sonst. MPN |
MDS |
ALL |
CLL |
sonst. |
ABL1
Mutationsanalyse |
|
|
x |
|
|
|
|
|
Ph+ |
|
|
| AF10_240-CALM |
|
x |
|
|
|
|
|
|
|
|
|
| ASXL1 |
|
x |
|
x |
x |
x |
CNL/aCML/CMML |
x |
|
|
Mastozytose |
| BCOR |
|
x |
|
|
|
|
|
(x) |
|
|
|
| BCR-ABL1 t(9;22) Translokation |
x |
x |
x |
|
|
|
|
|
x |
|
|
| BRAF |
x |
|
|
|
|
|
|
(x) |
|
|
HZL, Multiples Myelom |
B-Zell-
monoklona-
lität
IgVH |
x |
|
|
|
|
|
|
|
x |
x |
IgVH-Mutationsstatus (CLL) |
| CALR |
|
|
|
(x) |
x |
x |
RARS-T |
|
|
|
|
| CBFB-MYH11 Inv (16) Translokation |
x |
x |
|
|
|
|
|
|
|
|
|
| CBL |
|
x |
|
(x) |
(x) |
x |
aCML/CMML |
(x) |
|
|
Mastozytose |
| CEBPa |
|
x |
|
|
|
|
|
(x) |
|
|
|
| Chimaerismus |
x |
|
|
|
|
|
|
|
|
|
für transplantierte Patienten |
| CSFR3 |
|
|
|
|
|
|
CNL/aCML |
|
|
|
|
| CUX1 |
|
|
|
|
|
|
|
|
|
|
|
DEK-CAN
Translokation |
x |
x |
|
|
|
|
|
x |
|
|
|
| DNMT3A |
|
x |
|
x |
x |
x |
|
x |
T-ALL |
|
|
| ETV6 |
|
|
|
x |
x |
x |
x |
x |
|
|
|
| EZH2 |
|
(x) |
|
x |
(x) |
x |
CMML |
x |
|
|
|
| FLT3-ITD |
x |
x |
|
|
|
|
|
x |
x |
|
|
| FLT3-TKD |
|
x |
|
|
|
|
|
x |
x |
|
|
| GATA2 |
|
x |
|
|
|
|
|
|
|
|
|
| IDH1 |
x |
x |
|
(x) |
(x) |
x |
|
x |
T-ALL |
|
|
| IDH2 |
x |
x |
|
(x) |
(x) |
x |
|
x |
T-ALL |
|
|
| JAK2 Exon 12 |
|
|
|
x |
|
|
|
|
|
|
|
| JAK2 Exon 14 |
x |
|
|
x |
x |
x |
RARS-T/CMML |
x |
(x) B-ALL |
|
|
| KIT |
x |
x |
|
|
|
|
CMML |
(x) |
|
|
Mastozytose (E17) |
| KRAS |
x |
x |
|
|
|
|
aCML/CMML |
(x) |
|
|
|
| MLL-AF6 Translokation |
|
x |
|
|
|
|
|
|
x |
|
|
| MLL-AF9 Translokation |
|
x |
|
|
|
|
|
|
|
|
|
| MLL-ELL Translokation |
|
x |
|
|
|
|
|
|
|
|
|
| MLL-PTD Translokation |
|
x |
|
|
|
|
|
|
|
|
|
| MPL |
|
|
|
|
x |
x |
x |
(x) |
|
|
|
| MTHFR |
|
|
|
|
|
|
|
|
|
|
Hyperhomocysteinämie |
| MYD88 |
x |
|
|
|
|
|
CNL |
|
|
(x) |
B-NHL, Morbus Waldenström |
| NOTCH1 |
|
|
|
|
|
|
|
|
T-ALL |
x |
|
| NPM1 |
x |
x |
|
|
|
|
|
(x) |
|
|
|
| NPM1-MLF1 Translokation |
|
x |
|
|
|
|
|
x |
|
|
|
| NRAS |
x |
x |
|
|
|
|
aCML/CMML |
x |
|
|
|
| PHF6 |
|
x |
|
|
|
|
|
x |
T-ALL |
|
|
PML-RARA t (15;17)
Translokation |
x |
X (APL)
|
|
|
|
|
|
|
|
|
|
| PTPN11 |
|
x |
|
|
|
|
CMML |
(x) |
|
|
|
| RAD21 |
|
x |
|
|
|
|
|
|
|
|
|
| RUNX1 |
|
x |
|
x |
x |
x |
CMML |
x |
T-ALL |
|
|
RUNX1/RUNX1T1
t (8;21)Translokation |
x |
|
|
|
|
|
|
|
|
|
|
| SETBP1 |
|
|
|
|
|
|
CNL/aCML |
|
|
|
|
| SMC1A |
|
x |
|
|
|
|
|
|
|
|
|
| SMC3 |
|
x |
|
|
|
|
|
|
|
|
|
| SF3B1 |
|
x |
|
(x) |
(x) |
x |
RARS-T |
x |
|
x |
|
| SRSF2 |
|
x |
|
(x) |
(x) |
x |
CNL/aCML |
x |
|
|
|
| TET2 |
|
x |
|
x |
x |
x |
CMML |
x |
|
|
|
| TP53 |
|
x |
|
x |
x |
x |
CMML |
x |
(x) |
x |
Multiples Myelom |
| U2AF1 |
|
x |
|
(x) |
(x) |
x |
CNL |
x |
|
|
|
| UGT1A1 Polymorphismus |
|
|
|
|
|
|
|
|
|
|
bei Irinotecan-Therapie |
| WT1 |
|
x |
|
|
|
|
|
(x) |
|
|
|
| ZRSR2 |
|
x |
|
|
|
|
|
x |
|
|
|
Haben Sie Fragen zu Abnahme- oder Versandmodalitäten? Suchen Sie einen bestimmten Parameter, der hier nicht aufgeführt ist? Bitte rufen Sie uns an oder schicken Sie uns eine E-Mail unter (Kontakt)
